WNT3A and melanoma: A differential sensitivity was observed with simultaneous treatment of NRAS-mutant melanoma cells with WNT3A and AZD6244 (a MEK inhibitor); cell lines sensitive to apoptosis such as SK-MEL-2 and A375 showed an increased activation of the Wnt/β-catenin pathway and higher Axin2 levels, along with a decrease in Axin1 via proteosome through ERK inhibition [197].